Pfizer’s Hopes For Ibrance In Adjuvant Breast Cancer Fall With PALLAS
Ibrance (palbociclib) is unlikely to succeed in the adjuvant trial, the data safety monitoring board concluded. Pfizer has another adjuvant trial due later this year.
You may also be interested in...
With Lilly, Pfizer and Novartis duking it out for early-stage breast cancer patients, how many drugs for the same indication is too many?
The class is poised to be a competitive one with Sanofi, AstraZeneca, Roche and Zentalis among the contenders developing new selective estrogen receptor degraders for HER2-negative breast cancer.
Survival Data Boost Lilly & Novartis’s CDK4/6 Assault On Pfizer’s Ibrance In Metastatic Breast Cancer
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.